Latest Reolysin data 'confound' Oncolytics investors
This article was originally published in Scrip
Executive Summary
Oncolytics Biotech saw its stock price fall to its lowest point of the past year after the company touted Phase III data for Reolysin in the treatment head and neck cancer that showed an efficacy benefit, but only for certain patients treated in the study and without evidence of statistical significance in favor of the proprietary formulation of the human reovirus.